Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STVN Stock Forecast 2025-2026
$24.10
Current Price
$6.41B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to STVN Price Targets
+53.5%
To High Target of $37.00
+16.2%
To Median Target of $28.00
-0.4%
To Low Target of $24.00
STVN Price Momentum
+0.4%
1 Week Change
-2.7%
1 Month Change
+37.4%
1 Year Change
+10.6%
Year-to-Date Change
-6.4%
From 52W High of $25.75
+45.5%
From 52W Low of $16.56
📊 TOP ANALYST CALLS
Did STVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stevanato is one of their latest high-conviction picks.
Latest STVN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, STVN has a bullish consensus with a median price target of $28.00 (ranging from $24.00 to $37.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $24.10, the median forecast implies a 16.2% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 53.5% upside. Conversely, the most conservative target is provided by Derik De Bruin at B of A Securities, suggesting a 0.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STVN Analyst Ratings
8
Buy
2
Hold
0
Sell
STVN Price Target Range
Low
$24.00
Average
$28.00
High
$37.00
Current: $24.10
Latest STVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $23.50 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Outperform | Initiates | $28.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $26.00 |
| Dec 3, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Assumes | $23.00 |
| Aug 7, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $28.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $22.00 |
| Apr 22, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Mar 25, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $38.00 |
| Nov 1, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Nov 1, 2023 | Jefferies | David Windley | Hold | Downgrade | $29.00 |
| Sep 26, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $33.00 |
| Sep 19, 2023 | CJS Securities | Larry Solow | Market Outperform | Initiates | $36.00 |
| Aug 30, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $37.00 |
| Aug 24, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Downgrade | $34.00 |
| Jul 31, 2023 | Wells Fargo | Overweight | Maintains | $0.00 | |
| Jul 31, 2023 | Morgan Stanley | Overweight | Maintains | $0.00 | |
| Jul 17, 2023 | Morgan Stanley | Overweight | Reiterates | $0.00 | |
| Jun 26, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Reiterates | $29.00 |
| Jun 20, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Reiterates | $29.00 |
| Jun 16, 2023 | B of A Securities | Buy | Maintains | $0.00 |
Stevanato Group S.p.A. (STVN) Competitors
The following stocks are similar to Stevanato based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stevanato Group S.p.A. (STVN) Financial Data
Stevanato Group S.p.A. has a market capitalization of $6.41B with a P/E ratio of 44.3x. The company generates $1.30B in trailing twelve-month revenue with a 11.2% profit margin.
Revenue growth is +8.7% quarter-over-quarter, while maintaining an operating margin of +14.0% and return on equity of +9.1%.
Valuation Metrics
Market Cap
$6.41B
Enterprise Value
$7.75B
P/E Ratio
44.3x
PEG Ratio
39.1x
Price/Sales
5.7x
Growth & Margins
Revenue Growth (YoY)
+8.7%
Gross Margin
+27.2%
Operating Margin
+14.0%
Net Margin
+11.2%
EPS Growth
+40.9%
Financial Health
Cash/Price Ratio
+1.4%
Current Ratio
1.8x
Debt/Equity
27.9x
ROE
+9.1%
ROA
+4.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stevanato Group S.p.A. (STVN) Business Model
About Stevanato Group S.p.A.
What They Do
Manufactures medical equipment and packaging solutions.
Business Model
The company operates by providing a diverse range of medical equipment and packaging solutions, primarily serving the biopharmaceutical and diagnostic sectors. It generates revenue through the sale of glass primary packaging, integrated solutions for drug delivery, and engineering systems for pharmaceutical manufacturing, while fostering long-term partnerships with industry leaders.
Additional Information
Stevanato Group is recognized for its innovation and collaboration, which enhances customer loyalty and drives growth. Its strategic focus on technology-driven solutions and a global presence positions it well within the healthcare supply chain, ensuring the efficient delivery of advanced therapies and diagnostics.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
5,521
CEO
Mr. Franco Stevanato
Country
Italy
IPO Year
2021
Website
www.stevanatogroup.comStevanato Group S.p.A. (STVN) Latest News & Analysis
Latest News
Quick Summary
Investors in the Medical - Drugs sector may consider Grifols (GRFS) and Stevanato Group (STVN) as potential stock options for value investment.
Why It Matters
The comparison between Grifols and Stevanato Group highlights potential investment opportunities in the Medical - Drugs sector, signaling value-driven decisions for investors.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Stevanato Group S.p.A. (NYSE:STVN) will hold its Q1 2025 results conference call on May 8, 2025, at 8:30 AM ET, featuring key executives and financial analysts.
Why It Matters
Stevanato Group's Q1 2025 results call will provide insights into financial performance, management strategies, and market outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) will participate in three investor conferences, including a fireside chat at the Bank of America Securities Healthcare Conference on May 14, 2025.
Why It Matters
Stevanato Group's participation in key investor conferences signals active engagement with the investment community, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) reported a 9% increase in Q1 2025 revenue, reaching €256.6 million, with high-value solutions making up 43% of total revenue.
Why It Matters
Stevanato Group's 9% revenue growth and increasing share of high-value solutions indicate strong demand and potential for profitability, signaling positive momentum for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato Group (STVN) reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.10 and up from $0.09 per share the previous year.
Why It Matters
Stevanato Group's earnings beat estimates, indicating strong performance and potential growth, which can positively influence investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Drugs sector are considering Sandoz Group AG (SDZNY) and Stevanato Group (STVN) for potential value opportunities.
Why It Matters
Comparing Sandoz Group AG and Stevanato Group helps investors identify potential value plays in the Medical - Drugs sector, influencing portfolio decisions and market positioning.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About STVN Stock
What is Stevanato Group S.p.A.'s (STVN) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Stevanato Group S.p.A. (STVN) has a median price target of $28.00. The highest price target is $37.00 and the lowest is $24.00.
Is STVN stock a good investment in 2025?
According to current analyst ratings, STVN has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STVN stock?
Wall Street analysts predict STVN stock could reach $28.00 in the next 12 months. This represents a 16.2% increase from the current price of $24.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stevanato Group S.p.A.'s business model?
The company operates by providing a diverse range of medical equipment and packaging solutions, primarily serving the biopharmaceutical and diagnostic sectors. It generates revenue through the sale of glass primary packaging, integrated solutions for drug delivery, and engineering systems for pharmaceutical manufacturing, while fostering long-term partnerships with industry leaders.
What is the highest forecasted price for STVN Stevanato Group S.p.A.?
The highest price target for STVN is $37.00 from Paul Knight at Keybanc, which represents a 53.5% increase from the current price of $24.10.
What is the lowest forecasted price for STVN Stevanato Group S.p.A.?
The lowest price target for STVN is $24.00 from Derik De Bruin at B of A Securities, which represents a -0.4% decrease from the current price of $24.10.
What is the overall STVN consensus from analysts for Stevanato Group S.p.A.?
The overall analyst consensus for STVN is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are STVN stock price projections?
Stock price projections, including those for Stevanato Group S.p.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 4:58 PM UTC